US Dollar Index remains generally strong above 100.00 as concerns over escalating Iran tensions persist
US Dollar Index Holds Near Two-Week Peak Amid Middle East Tensions
During Monday's Asian session, the US Dollar Index (DXY)—which measures the dollar’s strength against a basket of six major currencies—edged slightly lower to around 100.15 after pulling back from an earlier high of 100.35. Despite this minor dip, the index remains close to its highest level in two weeks.
The US Dollar began the day on a stronger note, fueled by growing concerns over escalating conflict in the Middle East following reports of a potential US ground invasion of Iran. Rising geopolitical risks have increased demand for safe-haven assets like the dollar.
Last Thursday, the Wall Street Journal reported that the US Department of Defense is weighing the deployment of an additional 10,000 troops to Iran for possible ground operations. In response, Iran’s Parliament speaker Mohammad Bagher Ghalibaf warned, as reported by the BBC, that Iran would retaliate forcefully against any US military incursion.
A US ground offensive could further intensify the ongoing conflict in the Middle East, potentially disrupting energy supplies and driving oil prices higher. At present, WTI crude oil has surged by nearly 2.5%, trading above $102 per barrel.
Persistently elevated oil prices are prompting traders to anticipate tighter monetary policy from the Federal Reserve this year. The Fed’s hawkish outlook has been reinforced as rising oil costs have led to higher gasoline prices in the US.
Data from the CME FedWatch tool indicates that market participants have largely dismissed the possibility of a rate cut, now assigning a 24.6% probability to at least one rate hike by year-end—a significant shift from earlier expectations of two cuts before the conflict escalated.
In related news, President Donald Trump told the Financial Times that he is optimistic about reaching a swift agreement with Iran.
Looking ahead, the US economic calendar is busy this week, highlighted by the release of March’s Nonfarm Payrolls (NFP) data on Friday.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic files for IPO: lost $4.2 billion last year, revenue grew 12x to $4.6 billion, risk section warns of "threats to human survival"
Anthropic's IPO prospectus reveals that its spending on computing power and infrastructure will reach $7.33 billion in 2025, a twofold increase from 2024, accounting for more than half of its total operating expenses of $12.65 billion. The company plans to continue investing over $500 billion in the future. The risk section of the prospectus extends to 80 pages, explicitly warning that its AI models could pose "catastrophic or even existential threats," and may even resist shutdowns or manipulate information.
Meta shocks Wall Street by hiring MongoDB CEO and makes a high-profile entry into enterprise AI business
Meta has established an enterprise AI division called "Meta Enterprise Platform," which Mark Zuckerberg described as "the next important pillar." MongoDB CEO CJ Desai has been recruited to lead it. Analysts noted that Zuckerberg specifically poached a CEO from a publicly listed company to demonstrate the importance of this move. Desai's departure was announced just one day before Investor Day, with the timing surprising the public.
RBA set to hike interest rate to 4.60% in September as inflation remains elevated
AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose
This 18.6% premium subscription is not only a substantial endorsement, but both parties will also deeply collaborate on the joint development of combination therapies such as ADCs. The core of this deal is Akeso's Ivonescimab—the world’s first PD-1/VEGF bispecific antibody, and so far the only drug to have surpassed "K-drug" in head-to-head trials on both PFS and OS endpoints. The median OS reached 30.8 months, compared to 22.6 months for "K-drug", representing a 27% reduction in risk of death.
Crypto prices
More
